Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia

Maguire, Kay P.; Cheung, Peter; Crowley, Kathleen; Norman, Trevor R.; Schweitzer, Isaac; Burrows, Graham D.

doi:10.1016/s0920-9964(96)00092-8

Cited by 13 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serotonin receptor binding potential studies attempt to index serotonin receptor affinity or density by examining peripheral blood platelet binding (e.g., Coccaro, Kavoussi, Sheline, Lish, & Csernansky, 1996) or regional receptor density using positron emission tomography (Witte et al, 2009). Similar to other methods of assessing serotonin, binding potential studies have been characterized by inconsistent, contradictory, and null findings (e.g., Castrogiovanni, Capone, Maremmani, & Marazziti, 1994; Maguire et al, 1997; Marazziti & Conti, 1991). For example, the two published studies utilizing the high 5-HT 1A affinity radioligand [carbonyl-11C]WAY-100635 to measure the density of 5-HT 1A receptors in the prefrontal and anterior cingulate cortices and their relation to aggression found opposite results (Parsey et al, 2002; Witte et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Revisiting the serotonin–aggression relation in humans: A meta-analysis.

Duke¹,

Bègue²,

Bell³

et al. 2013

Psychological Bulletin

200

View full text Add to dashboard Cite

The inverse relation between serotonin and human aggression is often portrayed as “reliable,” “strong,” and “well-established” despite decades of conflicting reports and widely recognized methodological limitations. In this systematic review and meta-analysis we evaluate the evidence for and against the serotonin deficiency hypothesis of human aggression across four methods of assessing serotonin: (a) cerebrospinal fluid levels of 5-hydroxyindoleacetic acid (CSF 5-HIAA), (b) acute tryptophan depletion, (c) pharmacological challenge, and (d) endocrine challenge. Results across 175 independent samples and over 6,500 total participants were heterogeneous, but, in aggregate, revealed a small, inverse correlation between central serotonin functioning and aggression, anger, and hostility, r = −.12. Pharmacological challenge studies had the largest mean weighted effect size, r = −.21, and CSF 5-HIAA studies had the smallest, r = −.06, p = .21. Potential methodological and demographic moderators largely failed to account for variability in study outcomes. Notable exceptions included year of publication (effect sizes tended to diminish with time) and self-versus other-reported aggression (other-reported aggression was positively correlated to serotonin functioning). We discuss four possible explanations for the pattern of findings: unreliable measures, ambient correlational noise, an unidentified higher-order interaction, and a selective serotonergic effect. Finally, we provide four recommendations for bringing much needed clarity to this important area of research: acknowledge contradictory findings and avoid selective reporting practices; focus on improving the reliability and validity of serotonin and aggression measures; test for interactions involving personality and/or environmental moderators; and revise the serotonin deficiency hypothesis to account for serotonin’s functional complexity.

show abstract

Section: Discussionmentioning

confidence: 99%

Revisiting the serotonin–aggression relation in humans: A meta-analysis.

Duke¹,

Bègue²,

Bell³

et al. 2013

Psychological Bulletin

200

View full text Add to dashboard Cite

show abstract

“…Nine (1, 2, 4–10) of the 55 studies published that used SOAS assessments in some way (1–55) also presented results on the psychometric properties of the scale. In Table 1, studies on the reliability and validity of SOAS‐R measurements are arranged chronologically, along with the main statistical outcomes (e.g.…”

Section: Studies On the Psychometric Properties Of The Soasmentioning

confidence: 99%

“…Since Palmstierna and Wistedt presented the Staff Observation Aggression Scale (SOAS) in 1987 (1), however, many researchers have used this aggression‐monitoring tool (e.g. 2–55). Indeed, 15 years after its presentation in Acta Psychiatrica Scandinavica , there could be an opportunity to make a more significant comparison of aggression frequencies across countries and types of wards, as many studies have used an identical or very similar method for monitoring the behaviour.…”

Section: Introductionmentioning

confidence: 99%

Fifteen years of research with the Staff Observation Aggression Scale: a review

Nijman

Palmstierna

Almvik

et al. 2004

Acta Psychiatr Scand

145

133

View full text Add to dashboard Cite

show abstract

“…The authors concluded that this reflected state rather than trait aggression. However, Maguire et al (117) found no relationship between aggressive behavior and peripheral serotonin function as measured by [ 3 H]paroxetine binding to platelet membranes in 40 aggressive and nonaggressive schizophrenia patients. Pindolol, a 5-HT 1A antagonist, has been reported to reduce violence in aggressive schizophrenia patients when added to antipsychotic treatment (36).…”

Section: Aggressionmentioning

confidence: 99%

Fluvoxamine as an Adjunctive Agent in Schizophrenia

Silver

2001

CNS Drug Reviews

View full text Add to dashboard Cite

Schizophrenia is a common mental disorder that has an early onset and rates high as a cause of medical disability. Antipsychotic agents are the mainstay of treatment but response is often inadequate. Negative symptoms (disturbances in volition, social interaction and affective functions) are particularly difficult to treat and form a major obstacle to rehabilitation. A promising approach to improve response of negative symptoms has been to add a selective serotonin reuptake inhibitor (SSRI) antidepressant to antipsychotic treatment. This review examines evidence pertaining to the efficacy, tolerability, and safety of the SSRI fluvoxamine, combined with antipsychotic agents, in the treatment of negative symptoms in schizophrenia. Important methodological issues, such as differentiating primary and secondary negative symptoms, are discussed. The balance of available evidence indicates that fluvoxamine can improve primary negative symptoms in chronic schizophrenia patients treated with typical antipsychotics and suggests that it may also do so in some patients treated with clozapine. This combination is generally safe and well tolerated although, as antipsychotic drug concentrations may be elevated, attention to dose and drug monitoring should be considered appropriately. Combination with clozapine may require particular caution because of potential toxicity if serum clozapine levels rise steeply. The fluvoxamine doses effective in augmentation are lower than those usually used to treat depression. Evidence regarding the use of fluvoxamine augmentation to treat phenomena, such as obsessions and aggression, which may be associated with schizo-283

show abstract

Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia

Cited by 13 publications

References 18 publications

Revisiting the serotonin–aggression relation in humans: A meta-analysis.

Revisiting the serotonin–aggression relation in humans: A meta-analysis.

Fifteen years of research with the Staff Observation Aggression Scale: a review

Fluvoxamine as an Adjunctive Agent in Schizophrenia

Contact Info

Product

Resources

About